JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (JADE TEEN)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of PF-04965842 Co-Administered With Background Medicated Topical Therapy in Adolescent Participants 12 to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Category & Conditions:
Skin Diseases and Conditions
Medicine:
abrocitinib (PF-04965842)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B7451036
Open Plain Language Summary Result:Click here